A urine drug screen can be useful for objectively determining the presence of cannabinoids in a persons system. Cannabinoid metabolites (specifically 11-nor-Δ9-carboxylic acid) can be detected in urine for about 2–8 days with short-term use, and for 14–42 days of chronic use.It has been hypothesized that certain people may be genetically pre-disposed to metabolize cannabinoids in an atypical manner, making them susceptible to CHS.Other commonly used diagnostic tests include laboratory blood tests (complete blood count and differential, blood glucose, basic metabolic panel, pancreatic and liver enzymes), pregnancy test, urinalysis, and plain flat radiographic series.Prior to diagnosing and treating for a presumed CHS, more serious medical conditions need to be ruled out. Medical conditions that may present similarly to CHS include cyclic vomiting syndrome, bowel perforation or obstruction, gastroparesis, cholangitis, pancreatitis, nephrolithiasis, cholecystitis, diverticulitis, ectopic pregnancy, pelvic inflammatory disease, heart attack, acute hepatitis, adrenal insufficiency, and ruptured aortic aneurysm. In general, CHS is most often misdiagnosed as cyclic vomiting syndrome. However, if simple laboratory tests and imaging have excluded more serious conditions, it is reasonable to monitor for a worsening of the patients status to prevent the unnecessary application of more invasive, and potentially dangerous, diagnostic procedures (e.g. exploratory surgery). A complete history of the persons use of cannabinoids is important in establishing the correct diagnosis.CHS has often been undiagnosed, even for years.
Pancreatectomy (removal of a portion or nearly all of the pancreas) is usually a treatment of last resort when the less-drastic medical measures fail to provide prolonged normal blood sugar levels. For some time, the most common surgical procedure was removal of almost all of the pancreas; this cured some infants but not all. Insulin-dependent diabetes mellitus commonly develops, though in many cases it occurs many years after the pancreatectomy. Later it was discovered that a sizeable minority of cases of mutations were focal, involving overproduction of insulin by only a portion of the pancreas. These cases can be cured by removing much less of the pancreas, resulting in excellent outcomes with fewer long-term problems. History
This condition has been referred to by a variety of names in the past 50 years; nesidioblastosis and islet cell adenomatosis were favored in the 1970s, beta cell dysregulation syndrome or dysmaturation syndrome in the 1980s, and persistent hyperinsulinemic hypoglycemia of infancy (PHHI) in the 1990s. See also
Hyperammonemia
List of congenital disorders

References
Further reading
Hoyme, Louanne Hudgins; Toriello, Helga V.; Enns, Gregory M.; Hoyme, H. Eugene (2014). Signs and symptoms of genetic disease : a handbook. Oxford: Oxford University Press. ISBN 9780199930975. Hertz, David E., ed. (2005). Care of the newborn a handbook for primary care. Philadelphia: Lippincott Williams & Wilkins. ISBN 9780781755856. External links
PubMed